Areteia Therapeutics
Latest round
- Series A
Last raised
- Feb 2024
Total raised
- $275M
Investors
- 10
About Areteia Therapeutics
Based in North Carolina, US, Areteia Therapeutics, Inc. was created by Population Health Partners and Knopp Biosciences in 2022 and is a biopharmaceutical company in its clinical stage that develops an oral drug for eosinophilic asthma. In February 2024, Areteia Therapeutics, Inc. The company is conducting clinical trials of its oral medicine dexpramipexole, which has the potential to target eosinophils in the blood and prevent them from traveling through the blood to the lungs of people suffering from eosinophilic asthma and reducing their effect on the lungs before they cause further damage.
Who invested in Areteia Therapeutics
10 investors across 2 rounds
See all investors in Areteia Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Areteia Therapeutics
Who invested in Areteia Therapeutics?
Areteia Therapeutics has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Areteia Therapeutics raised?
Areteia Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Areteia Therapeutics last raise money?
Areteia Therapeutics's most recent round on record is a Series A, in Feb 2024.
What does Areteia Therapeutics do?
Based in North Carolina, US, Areteia Therapeutics, Inc.
Where is Areteia Therapeutics headquartered?
Areteia Therapeutics is headquartered in Chapel Hill, US.
Which VCs invest in companies like Areteia Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Areteia Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Areteia Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.